Muscle spasticity refers to a condition in which certain muscles are continuously contracted (tightened) and cannot be easily controlled. It occurs due to damage to the brain or spinal cord resulting in tightening of muscles. Muscle spasticity treatment involves medications such as baclofen, diazepam and botulinum toxin injection and baclofen pump implants to control the tightness of muscles and increase range of motion. The global muscle spasticity market is driven by the growing prevalence of neurodegenerative disorders, frequent product launches and growing demand for minimally invasive treatments.

The Global Muscle Spasticity Market is estimated to be valued at US$ 5693.7 Mn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2030.

Key Takeaways
Key players operating in the muscle spasticity market are Accenture PLC,Cisco Systems Inc.,Cognizant Technology Solutions Corporation,Capgemini,Computer Sciences Corporation (CSC),HCL Technologies Ltd.,IBM Corporation,Infosys Ltd.,Intel Corporation,Jabil Circuits,Micron Technology,NTT Data Corporation,Tata Consultancy Services,Tech Mahindra Ltd.,Wipro Ltd. Rising demand for botulinum toxin for effective spasticity management is a major factor driving industry growth. Technological advancements in drug delivery systems, such as dosage forms, are improving patient compliance and clinical outcomes in spasticity treatment.

The major opportunities in the Muscle Spasticity Market Growth include development of novel drug formulations, gene therapies and intensive research on neurogenesis. Furthermore, inorganic growth strategies like mergers and acquisitions among industry players is projected to boost the global market revenues.

Market Trends
Increasing government spending on healthcare infrastructure development across developing nations will support the market expansion over the coming years. Additionally, clinical trials to evaluate the efficacy and safety of new chemical entities are anticipated to offer new treatment options.

Market Opportunities
Rising demand for minimally invasive products and increasing geriatric population susceptible to chronic conditions like cerebral palsy, multiple sclerosis and stroke presents lucrative business opportunities for market players. Furthermore, research and development of gene therapies for genetic neurological disorders like spinal muscular atrophy presents attractive opportunities.

Impact of COVID-19 on the Muscle Spasticity Market

The outbreak of the COVID-19 pandemic has negatively impacted the muscle spasticity market. Various lockdowns and containment measures have disrupted the production and supply chain of pharmaceutical companies. However, the demand for treatments of muscle spasticity among patients remains largely unchanged. The pandemic led to restrictions on non-essential hospital visits and treatments for a certain period. This resulted in postponed procedures and decline in new patient registrations for muscle spasticity treatment, thereby affecting the market growth initially. However, with restrictions now being gradually lifted in many countries and healthcare systems adapting to the new normal, the market is witnessing recovery. Pharmaceutical companies have also enhanced their online presence and delivery capabilities to continue serving patients amid restrictions. Going forward, the market is expected to return to its forecasted growth trajectory, driven by factors such as increasing awareness, approvals of new drugs and treatment devices, and healthcare expenditure. The post-COVID scenario will witness more focus on telemedicine, digital healthcare solutions, and home care services for effective management of muscle spasticity patients.

North America dominates the global Muscle Spasticity Market in terms of value.

North America currently dominates the global muscle spasticity market, accounting for over 40% share in terms of value. This is attributed to high awareness levels regarding available treatment options, strong healthcare infrastructure, and favorable reimbursement policies in countries like the US and Canada. Moreover, the presence of top players in the region is boosting market growth. Going forward, the markets in Asia Pacific and Latin America are expected to grow at the fastest pace, driven by improving access to healthcare facilities, rising medical tourism, growing geriatric population, and expanding middle-class demographics.

Asia-Pacific to emerge as the fastest growing region in the Muscle Spasticity Market

Asia Pacific region is poised to offer most lucrative growth opportunities for players operating in the global muscle spasticity market over the forecast period. This is majorly attributed to rapidly developing healthcare infrastructure, growing awareness about the condition and available treatments, increasing personal disposable incomes, growing medical tourism, and presence of less stringent regulations. Moreover, countries like China and India have a massive population base with high unmet needs. Pharmaceutical companies are investing heavily in these emerging markets through partnerships with regional players. Other factors driving the demand in Asia Pacific region include improving accessibility of latest treatment devices, growing geriatric population, and increasing preference towards less invasive procedures. As a result, the Asia Pacific market for muscle spasticity is anticipated to expand at the fastest CAGR of over 13% during the forecast years.

Get More Insights On This Topic: Muscle Spasticity Market